Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Liabilities and Shareholders Equity (2019 - 2025)

Silence Therapeutics' Liabilities and Shareholders Equity history spans 7 years, with the latest figure at $131.4 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 35.13% year-over-year to $131.4 million; the TTM value through Dec 2025 reached $628.8 million, up 210.29%, while the annual FY2025 figure was $131.4 million, 35.13% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $131.4 million at Silence Therapeutics, down from $146.8 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $202.6 million in Q4 2024 and bottomed at $116.4 million in Q4 2023.
  • The 5-year median for Liabilities and Shareholders Equity is $139.1 million (2025), against an average of $150.5 million.
  • The largest annual shift saw Liabilities and Shareholders Equity surged 74.01% in 2024 before it plummeted 35.13% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $129.7 million in 2021, then dropped by 2.76% to $126.1 million in 2022, then decreased by 7.65% to $116.4 million in 2023, then soared by 74.01% to $202.6 million in 2024, then tumbled by 35.13% to $131.4 million in 2025.
  • Per Business Quant, the three most recent readings for SLN's Liabilities and Shareholders Equity are $131.4 million (Q4 2025), $146.8 million (Q3 2025), and $165.2 million (Q2 2025).